Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia - PubMed (original) (raw)
Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia
R Pieters et al. Lancet. 1991.
Abstract
The clinical relevance of cellular drug resistance in children with acute lymphoblastic leukaemia (ALL) is unknown. The relation between in-vitro sensitivity to chemotherapeutic drugs at initial diagnosis and long-term clinical outcome was investigated in 44 children with ALL. The short-term MTT assay was used to assess sensitivity to prednisolone, vincristine, colaspase (asparaginase), daunorubicin, and thioguanine (instead of mercaptopurine which is unstable in vitro). For vincristine and colaspase there was no difference in outcome (probability of continuous complete remission) between sensitive and resistant patients. However, the probability of continuous complete remission was significantly lower in patients with resistant cells than in those with sensitive cells for thioguanine (p less than 0.01), daunorubicin (p less than 0.02), and prednisolone (p less than 0.05). For prednisolone there was a significant worsening of the prognosis (p less than 0.05) from the extremely sensitive patients through an intermediate group to the most resistant group. The prognostic significance of cellular drug resistance was independent of white-blood-cell count, age, sex, and hepatosplenomegaly. Leukaemic cells from boys were more resistant to thioguanine than those from girls. Thus, the short-term highly efficient MTT assay can help to predict long-term response to chemotherapy in childhood ALL.
Similar articles
- In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R. Hongo T, et al. Blood. 1997 Apr 15;89(8):2959-65. Blood. 1997. PMID: 9108416 - Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia.
Pieters R, Kaspers GJ, van Wering ER, Huismans DR, Loonen AH, Hählen K, Veerman AJ. Pieters R, et al. Leukemia. 1993 Mar;7(3):392-7. Leukemia. 1993. PMID: 8445945 - In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia.
Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk CH, Smets LA, Van Wering ER, Van Der Does-Van Den Berg A. Kaspers GJ, et al. Blood. 1997 Oct 1;90(7):2723-9. Blood. 1997. PMID: 9326239 - Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines.
Ronghe M, Burke GA, Lowis SP, Estlin EJ. Ronghe M, et al. Cancer Treat Rev. 2001 Dec;27(6):327-37. doi: 10.1053/ctrv.2001.0243. Cancer Treat Rev. 2001. PMID: 11908926 Review. - The clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukaemia.
Estlin EJ, Ronghe M, Burke GA, Yule SM. Estlin EJ, et al. Br J Haematol. 2000 Sep;110(4):780-90. doi: 10.1046/j.1365-2141.2000.t01-1-02153.x. Br J Haematol. 2000. PMID: 11054059 Review. No abstract available.
Cited by
- Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia.
Yoshimura S, Li Z, Gocho Y, Yang W, Crews KR, Lee SHR, Roberts KG, Mullighan CG, Relling MV, Yu J, Yeoh AEJ, Loh ML, Saygin C, Litzow MR, Jeha S, Karol SE, Inaba H, Pui CH, Konopleva M, Jain N, Stock W, Paietta E, Jabbour E, Kornblau SM, Evans WE, Yang JJ. Yoshimura S, et al. J Clin Oncol. 2024 Oct 10;42(29):3478-3490. doi: 10.1200/JCO.24.00500. Epub 2024 Aug 5. J Clin Oncol. 2024. PMID: 39102629 - c-Myb interacts with the glucocorticoid receptor and regulates its level in pre-B-acute lymphoblastic leukemia cells.
Sarvaiya PJ, Schwartz JR, Geng CD, Vedeckis WV. Sarvaiya PJ, et al. Mol Cell Endocrinol. 2012 Sep 25;361(1-2):124-32. doi: 10.1016/j.mce.2012.03.024. Epub 2012 Apr 10. Mol Cell Endocrinol. 2012. PMID: 22516378 Free PMC article. - Cytotoxic effects of vitamin A in combination with vincristine, daunorubicin and 6-thioguanine upon cells from lymphoblastic leukemic patients.
Pieters R, Huismans DR, Loonen AH, Hählen K, Veerman AJ. Pieters R, et al. Jpn J Cancer Res. 1991 Sep;82(9):1051-5. doi: 10.1111/j.1349-7006.1991.tb01942.x. Jpn J Cancer Res. 1991. PMID: 1938600 Free PMC article. - Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing.
Hongo T, Okada S, Inoue N, Yamada S, Yajima S, Watanabe C, Fujii Y, Horikoshi Y. Hongo T, et al. Int J Hematol. 2002 Oct;76(3):251-9. doi: 10.1007/BF02982795. Int J Hematol. 2002. PMID: 12416736 - Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia.
Steeghs EMP, Boer JM, Hoogkamer AQ, Boeree A, de Haas V, de Groot-Kruseman HA, Horstmann MA, Escherich G, Pieters R, den Boer ML. Steeghs EMP, et al. Sci Rep. 2019 Mar 15;9(1):4634. doi: 10.1038/s41598-019-41078-4. Sci Rep. 2019. PMID: 30874617 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources